Marc Elia is the founder of M28 Capital, a healthcare sector investment fund. Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund. He is on the Board of Directors of Adagio Therapeutics, Adimab and SQZ Biotechnologies. Mr. Elia holds a B.A. in economics from Carleton College.